| Bioactivity | Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production[1][2]. |
| Invitro | Resolvin E1 (0.1-100 nM) gives concentration-dependent inhibition of TNF-α–induced NF-κB activation with an EC50 of ∼1.0 nM in ChemR23-transfected cells. Resolvin E1 (100 nM) increases phosphorylation of extracellular signal-regulated kinase (ERK) mitogen-activated protein (MAP) kinase both in peripheral blood monocytes and HEK-ChemR23 cells[2].Resolvin E1 specifically interacts with the LTB4 receptor BLT1 on neutrophils and ChemR23 on monocytes to regulate leukocytes during inflammation. Resolvin E1 also stimulates the uptake and clearance of local cytokine[3]. |
| Name | Resolvin E1 |
| CAS | 552830-51-0 |
| Formula | C20H30O5 |
| Molar Mass | 350.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Solution, -20°C, 2 years |
Resolvin E1
CAS: 552830-51-0 F: C20H30O5 W: 350.45
Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicos
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.